Evidence map›Paper›PMID 25897748›Full record

ArticleAnnals of the American Thoracic Society2015

An official American Thoracic Society workshop report: stem cells and cell therapies in lung biology and diseases.

Daniel J Weiss, Daniel Chambers, Adam Giangreco, Armand Keating, Darrell Kotton, Peter I Lelkes, Darcy E Wagner, Darwin J Prockop, ATS Subcommittee on Stem Cells and Cell Therapies

2 registry-linked trialsOpen access · greenAbstract readConference Proceedings
In one paragraph

Article in Annals of the American Thoracic Society, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
4.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02625246 phase1completednot on this mapstarted 2016, after this paper: background citation

A Phase I, Trial to Evaluate the Safety, Tolerability, and Potential Efficacy of Allogeneic Human Mesenchymal Stem Cell (hMSC) Infusion in Patients With Non-Cystic Fibrosis Bronchiectasis

TypeinterventionalSponsorMarilyn GlassbergRan2016 to 2019Enrolled6ConditionsBronchiectasisArmshMSCs
NCT03137199 phase1terminatednot on this mapstarted 2017, after this paper: background citation

A Phase I, Trial to Evaluate the Safety, Tolerability, and Potential Efficacy of Allogeneic Human Mesenchymal Stem Cell Infusion in Patients With Mild Asthma

TypeinterventionalSponsorMarilyn GlassbergRan2017 to 2020Enrolled3ConditionsAsthmaArmshMSCs
3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 30 citations in OpenAlex.

  1. Stem cells, cell therapies, and bioengineering in lung biology and diseases 2023.American journal of physiology. Lung cellular and molecular physiology · 2024
    Review
  2. Article
  3. Circulating SSEA-1Cellular and molecular life sciences : CMLS · 2022
    Article
  4. Article
  5. Review
  6. Review
  7. Amphiregulin modulates murine lung recovery and fibroblast function following exposure to agriculture organic dust.American journal of physiology. Lung cellular and molecular physiology · 2020
    Article
  8. Article
  9. Endosomal signalling via exosome surface TGFβ-1.Journal of extracellular vesicles · 2019
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Daniel J Weiss
Daniel Chambers
Adam Giangreco
Armand Keating
Darrell Kotton
Peter I Lelkes
Darcy E Wagner
Darwin J Prockop
ATS Subcommittee on Stem Cells and Cell Therapies
European Respiratory Society · CHPulmonary Fibrosis Foundation · USUniversity of Vermont · USVermont Department of Health · US

Funding

Stem Cells and Cell Therapies in Lung Biology and DiseasesR13HL097533 · NHLBI · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI WEISS, DANIEL J · 2009 to 2011
$55k
NHLBI NIH HHS R13 HL097533
6 · The paper itself

Abstract

The University of Vermont College of Medicine and the Vermont Lung Center, in collaboration with the NHLBI, Alpha-1 Foundation, American Thoracic Society, European Respiratory Society, International Society for Cell Therapy, and the Pulmonary Fibrosis Foundation, convened a workshop, "Stem Cells and Cell Therapies in Lung Biology and Lung Diseases," held July 29 to August 1, 2013 at the University of Vermont. The conference objectives were to review the current understanding of the role of stem and progenitor cells in lung repair after injury and to review the current status of cell therapy and ex vivo bioengineering approaches for lung diseases. These are all rapidly expanding areas of study that both provide further insight into and challenge traditional views of mechanisms of lung repair after injury and pathogenesis of several lung diseases. The goals of the conference were to summarize the current state of the field, discuss and debate current controversies, and identify future research directions and opportunities for both basic and translational research in cell-based therapies for lung diseases. This conference was a follow-up to four previous biennial conferences held at the University of Vermont in 2005, 2007, 2009, and 2011. Each of those conferences, also sponsored by the National Institutes of Health, American Thoracic Society, and Respiratory Disease Foundations, has been important in helping guide research and funding priorities. The major conference recommendations are summarized at the end of the report and highlight both the significant progress and major challenges in these rapidly progressing fields.

Indexed as

Stem Cell TransplantationTissue EngineeringCell- and Tissue-Based TherapyEmbryonic Stem CellsHumansInduced Pluripotent Stem CellsLungLung DiseasesMesenchymal Stem CellsNational Heart, Lung, and Blood Institute (U.S.)Societies, MedicalStem CellsTracheal DiseasesUnited States

Identifiers

PMID25897748
PMCPMC5466184
OpenAlexW4232139998

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.